论文部分内容阅读
目的探讨酮替芬联合孟鲁司特治疗慢性喘息型支气管炎的临床疗效。方法随机将我院2009年3月至2011年12月间收治的118例慢性喘息型支气管炎患者分为观察组和对照组,每组各59例,两组患者均给予常规综合治疗,对照组患者在此基础上加用孟鲁司特治疗,观察组患者在此基础上采用酮替芬联合孟鲁司特治疗,观察两组患者的临床疗效。结果观察组患者治疗总有效率为93.2%,显著高于对照组患者的74.6%,组间差异有统计学意义(P<0.05),两组患者在治疗过程中少数出现头痛、心悸症状,未见其他严重不良反应。结论采用酮替芬联合孟鲁司特治疗慢性喘息型支气管炎临床疗效确切,不良反应发生率低,临床应用较为安全可靠,值得广泛推广使用。
Objective To investigate the clinical efficacy of ketotifen combined with montelukast in the treatment of chronic asthmatic bronchitis. Methods A total of 118 patients with chronic asthmatic bronchitis treated in our hospital from March 2009 to December 2011 were randomly divided into observation group and control group, 59 cases in each group. The patients in both groups were given conventional comprehensive treatment and the control group On this basis, the patients were treated with montelukast. The patients in the observation group were treated with ketotifen and montelukast on the basis of this observation. The clinical efficacy of the two groups was observed. Results The total effective rate of the observation group was 93.2%, which was significantly higher than that of the control group (74.6%). The difference between the two groups was statistically significant (P <0.05). There were a few cases of headache, palpitation symptoms, See other serious adverse reactions. Conclusion Ketotifen combined with montelukast in the treatment of chronic asthmatic bronchitis clinical curative effect, the incidence of adverse reactions is low, the clinical application of more safe and reliable, it is widely used.